This site is intended for health professionals only

Thursday 27 June 2019

Anja St Clair Jones MSc Dip Pharm

Articles by this author

Thu 25 April
Thu 25 April
Non-alcoholic fatty liver disease is an area of extremely fast development of new treatments and careful attention and pharmaceutical expertise will be required to develop the treatment strategies to deal with the explosive growth of patients diagnosed with NAFLD and NASH
Mon 4 March
Mon 4 March
Could dose de-escalation be an alternative strategy to decrease drug exposure, related risk, and treatment‐related costs while maintaining clinical remission in IBD?